Last reviewed · How we verify
SOM0226
At a glance
| Generic name | SOM0226 |
|---|---|
| Sponsor | SOM Innovation Biotech SA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder (PHASE2)
- Remediation of Impaired Self-Regulation in Patients With Mild TBI (EARLY_PHASE1)
- Gait Analysis in Neurological Disease
- COMT Inhibition Among Individuals With Comorbid AUD/ADHD (PHASE2)
- Microbiome Derived Metabolism and Pharmacokinetics (PHASE1)
- Effects of Tolcapone on Frontotemporal Dementia (PHASE2)
- Trial of Tolcapone With Oxaliplatin for Neuroblastoma (PHASE1)
- Dopaminergic Mechanisms Underlying Human Social Behavior (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOM0226 CI brief — competitive landscape report
- SOM0226 updates RSS · CI watch RSS
- SOM Innovation Biotech SA portfolio CI